Pemirolast
![]() | |
Systematic (IUPAC) name | |
---|---|
9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one | |
Clinical data | |
Trade names | Alamast |
AHFS/Drugs.com | monograph |
Pregnancy category |
|
Legal status |
|
Routes of administration | Oral, ophthalmic |
Identifiers | |
CAS Number |
69372-19-6 ![]() |
ATC code | None |
PubChem | CID 57697 |
IUPHAR/BPS | 7329 |
DrugBank |
DB00885 ![]() |
ChemSpider |
51990 ![]() |
UNII |
2C09NV773M ![]() |
KEGG |
D07476 ![]() |
ChEMBL |
CHEMBL1201198 ![]() |
Chemical data | |
Formula | C10H8N6O |
Molar mass | 228.21 g/mol |
| |
![]() ![]() |
Pemirolast (INN) is a mast cell stabilizer used as an anti-allergic drug therapy. It is marketed under the tradenames Alegysal and Alamast.
It has also been studied for the treatment of asthma.
References
- Tinkelman DG, Berkowitz RB (February 1991). "A pilot study of pemirolast in patients with seasonal allergic rhinitis". Ann Allergy 66 (2): 162–5. PMID 1994787.
- Kawashima T, Iwamoto I, Nakagawa N, Tomioka H, Yoshida S (1994). "Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils". Int. Arch. Allergy Immunol. 103 (4): 405–9. doi:10.1159/000236662. PMID 8130655.
- Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL (October 2002). "Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies". J Ocul Pharmacol Ther 18 (5): 475–88. doi:10.1089/10807680260362759. PMID 12419098.
- Kemp JP, Bernstein IL, Bierman CW, et al. (June 1992). "Pemirolast, a new oral nonbronchodilator drug for chronic asthma". Ann Allergy 68 (6): 488–91. PMID 1610024.
External links
- Mitsubishi Tanabe Pharma Corporation (2007). "ALEGYSAL (English)" (PDF). Retrieved 2008-09-02.
- "DailyMed Announcements". U.S. National Library of Medicine. 2005. Retrieved 2008-09-02.
|
This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.